Pharmaceutical drug companies operate in heavily regulated markets where they must comply with federal clinical trials and also rely on intellectual property protection to protect investments in research and development that can yield drug compounds that cost hundreds of millions of dollar to discover, test and produce. How will drug companies use the law to create value and manage risk across the various value chain activities?